Tesaro Shares Tumble After Disappointing Data Results
December 23, 2013 at 13:24 PM EST
Shares of Tesaro (NASDAQ: TSRO ) dropped as much as 32.19% to $28.52 following the announcement that data from two trials showed that rolapitant for chemotherapy induced nausea and vomiting (CINV) missed secondary endpoints. BMO Capital Markets analyst Jim Birchenough reported that investors had expected Tesaro's rolapitant to differentiate
